Conjugated meningococcal capsular saccharides will be introduced intoimmunisation schedules in the near future, but the phenomenon of "carriersuppression" must first be addressed, particularly where multiple conjugatesare to be used. In the invention, tetanus toxoid is used as the carrierprotein, even where multiple meningococcal conjugates are administered at thesame time and where a patient has previously been exposed to the carrierprotein, either in the form of a previous immunogen (e.g. in a DTP vaccine) oras a previous carrier protein (e.g. in a Hib or pneumococcal conjugatevaccine). The invention provides a method for immunising a patient, comprisingadministering multiple conjugates of meningococcal capsular saccharides,wherein each conjugate comprises a tetanus toxoid carrier protein, and thecapsular saccharide, and wherein the patient has been pre-immunised with atetanus toxoid.
